A$107 million cash balance as Echo IQ replaces CEO with interim leader

Echo IQ CEO Dustin Haines has resigned, with Executive Chairman Andrew Grover taking over as Interim CEO from 23 November. The leadership change comes as the company turns its attention to US commercial rollout, reimbursement and the unresolved regulatory path for EchoSolv HF.

  • Dustin Haines resigns as CEO effective 23 November 2026
  • Andrew Grover assumes the Interim CEO role without changes to his contract
  • Echo IQ reported approximately A$107 million in cash at 30 September 2026
  • Immediate focus shifts to US rollout and EchoSolv AS reimbursement
  • EchoSolv HF remains uncleared and unavailable for US commercial sale
An image related to EchoIQ Limited A photo of the logo for EchoIQ Add us as a preferred source on Google
Image © middle. Logo © respective owner.

Chairman Takes Control After CEO Resignation

Echo IQ Limited (ASX:EIQ) is changing chief executives at a consequential point in its commercial development. Dustin Haines has resigned as CEO effective 23 November 2026, with Executive Chairman Andrew Grover assuming the additional role of Interim CEO.

The announcement does not give a reason for Mr Haines’ departure or set a timetable for appointing a permanent successor. That leaves Mr Grover responsible for maintaining momentum while the company works through the practical challenges of selling an FDA-cleared product in the United States.

Grover Returns With Commercial Priorities

Mr Grover has been a director since 2019 and previously served as acting CEO from October 2021 to January 2025. Echo IQ credits him with helping guide the business from research and development towards an FDA-cleared medical technology company, including the October 2024 clearance of EchoSolv AS and the development of relationships with US healthcare institutions.

The company’s financial buffer is substantial on the figures disclosed: cash at bank stood at approximately A$107 million at 30 September. That balance was reported alongside a September-quarter assessment surge, when earlier coverage recorded 9,697 full-result EchoSolv AS assessments. Echo IQ says the funds support its commercial rollout, regulatory work and broader clinical development, although the filing provides no new spending forecasts or financial targets.

EchoSolv Reimbursement and HF Regulation in Focus

Mr Grover’s immediate priorities are to advance the US rollout of EchoSolv AS, progress reimbursement pathways and determine the regulatory strategy for EchoSolv HF. The latter remains a material qualification: EchoSolv HF is not FDA-cleared and is not available for commercial sale in the United States.

The regulatory issue follows a EchoSolv HF appeal review that gave Echo IQ a formal route to seek reconsideration of the regulator’s earlier determination, without changing that determination or guaranteeing clearance. The company now says it will review its regulatory strategy, but has not identified the route it will pursue or attached a timetable to the process.

Echo IQ says its existing operational, clinical, technical and commercial leaders provide continuity, with Dr Vasum Peiris’ recent appointment as Executive Vice President and Chief Medical Officer adding clinical and regulatory expertise. The immediate test for the interim arrangement is whether that continuity can translate into reimbursement progress and commercial execution while the board’s longer-term leadership plans remain unstated.

Get ASX:EIQ news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The cash runway supports execution, but the next signals will come from US commercial conversion, reimbursement progress and a clearer permanent CEO plan.

Questions in the middle?

  • How quickly will Echo IQ appoint a permanent CEO, and will the role carry a different commercial or regulatory mandate?
  • What reimbursement milestones can EchoSolv AS achieve in the US, and how will they affect adoption?
  • Which regulatory pathway will Echo IQ select for EchoSolv HF, and what evidence or timing will it require?

Sources

1